NUREXONE BIOLOGIC INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5 CAD | +4.17% |
|
-3.85% | +69.49% |
| 29/05 | NurExone Biologic Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 25/04 | NurExone Biologic Announces OTCQB Listing And DTC Eligibility | MT |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 12.25 | 10.75 | 24.51 | - | - |
| Enterprise Value (EV) 1 | 12.25 | 10.75 | 24.51 | 24.51 | 24.51 |
| P/E ratio | -1.32 x | -2.75 x | -4.57 x | -4.57 x | -7.31 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 42,855 | 48,250 | 67,105 | - | - |
| Reference price 2 | 0.2858 | 0.2228 | 0.3653 | 0.3653 | 0.3653 |
| Announcement Date | 30/03/23 | 02/04/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -3.657 | -4.62 | -4.75 | - |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -3.639 | -4.669 | -4.737 | - |
| Net income 1 | -8.169 | -3.639 | -4.669 | -4.737 | - |
| Net margin | - | - | - | - | - |
| EPS 2 | -0.2160 | -0.0810 | -0.0800 | -0.0800 | -0.0500 |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 30/03/23 | 02/04/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -1.06 | -1.164 | -0.716 | -0.92 | -1.1 | -1.2 | -1.4 | -1.05 | -1.1 |
| Operating Margin | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -1.04 | -1.158 | -0.737 | -0.922 | -1.101 | -1.201 | -1.401 | -1.035 | -1.101 |
| Net income 1 | -1.04 | -1.158 | -0.737 | -0.922 | -1.101 | -1.201 | -1.401 | -1.035 | -1.101 |
| Net margin | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.0240 | -0.0260 | -0.0150 | -0.0160 | -0.0200 | -0.0200 | -0.0200 | -0.0200 | -0.0200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 28/08/23 | 24/11/23 | 02/04/24 | 29/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Net Cash position | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share | - | - | - | - |
| Cash Flow per Share | - | - | - | - |
| Capex | - | - | - | - |
| Capex / Sales | - | - | - | - |
| Announcement Date | 30/03/23 | 02/04/24 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.3653
USD
Average target price
2.918
USD
Spread / Average Target
+698.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +69.49% | 2.44Cr | |
| +51.85% | 5.79TCr | |
| +41.42% | 4.03TCr | |
| -5.25% | 3.99TCr | |
| -5.16% | 2.85TCr | |
| +12.79% | 2.64TCr | |
| -20.18% | 1.93TCr | |
| +30.88% | 1.24TCr | |
| +0.61% | 1.22TCr | |
| +25.06% | 1.22TCr |
- Stock Market
- Equities
- NRX Stock
- Financials NurExone Biologic Inc.
